Cat. No.: DAB-0012082
Product Information | |
---|---|
Clonality | Monoclonal |
Host Species | Rabbit |
Product Description | Monoclonal antibodies were produced by immunizing animals with a synthetic peptide corresponding to the respective sequences of human GAPDH, Hexokinase I, Hexokinase II, LDHA, PKM2, Pyruvate Dehydrogenase or PFKP protein. |
Format | Liquid |
Purity | Affinity purity |
Target Information | |
---|---|
Gene Description | Glycolysis is the metabolic process by which glucose is converted to pyruvate in a sequence of enzymatic steps. Hexokinase catalyzes the conversion of glucose to glucose-6-phosphate, the first step in glycolysis. Hexokinases I, II, and III are associated with the outer mitochondrial membrane and are critical for maintaining an elevated rate of aerobic glycolysis in cancer cells. Phosphofructokinase catalyzes the phosphorylation of fructose-6-phosphate. Platelet-type phosphofructokinase is expressed in various cell types. Glyceraldehyde-3-phosphate dehydrogenase catalyzes the phosphorylation of glyceraldehyde-3-phosphate. Pyruvate kinase, a glycolytic enzyme, catalyses the conversion of phosphoenolpyruvate to pyruvate. In mammals, the M1 isoform is expressed in most adult tissues. The M2 isoform, an alternatively-spliced variant of M1, is expressed during embryonic development. Lactate dehydrogenase catalyzes the interconversion of pyruvate and NADH to lactate and NAD+. LDHA expression is induced when the oxygen supply is too low for mitochondrial ATP production. The pyruvate dehydrogenase complex catalyzes the conversion of pyruvate and CoA into acetyl-CoA and CO2 in the presence of NAD+. The reaction of oxidative decarboxylation of pyruvate serves as a critical link between glycolysis and the citric acid cycle and lipid metabolism. |
Shipping & Storage | |
---|---|
Shipping | Shipped at 4 °C. |
Storage Instructions | Store at +4 °C short term (1-2 weeks). Store at -20 °C long term. |
Storage Buffer | Constituent: 100% PBS |
Ace Therapeutics has a team of experts in the field of endocrine and metabolic research, aiming to provide innovative preclinical contract research solutions to cope with diabetes and its complications. We provide customized solutions and technical support, enabling the transformation of promising concepts into innovative treatments, thus accelerating the drug development process of diabetes.